Dr. Ebell and Dr. Wilkes discuss the POEM titled ' Monoclonal antibodies for Alzheimer disease: A lack of clinically meaningful benefits, plus significant harms '

Episode 695: Monoclonal antibodies for Alzheimer disease: A lack of clinically meaningful benefits, plus significant harms

Each week, Dr. Mark Ebell, POEMs Editor, joins Dr. Michael Wilkes, NPR correspondent and Vice-Dean of the UC-Davis Medical School, for a five minute discussion about an important recent medical study reviewed by the POEMs editors. POEMs provide synopsised reviews of studies that could affect a clinician's practice, and the discussion in this podcast provides additional depth and insight into the issue covered by the POEMs synopsis.  More about POEMs and it's companion point-of-care search tool, Essential Evidence Plus, at www.essentialevidenceplus.com.

Medicine

Each week, Dr. Mark Ebell, POEMs Editor, joins Dr. Michael Wilkes, NPR correspondent and Vice-Dean of the UC-Davis Medical School, for a five minute discussion about an important recent medical study reviewed by the POEMs editors. POEMs provide synopsised reviews of studies that could affect a clinician's practice, and the discussion in this podcast provides additional depth and insight into the issue covered by the POEMs synopsis. More about POEMs and it's companion point-of-care search tool, Essential Evidence Plus, at www.essentialevidenceplus.com.

Share Episode 695: Monoclonal antibodies for Alzheimer disease: A lack of clinically meaningful benefits, plus significant harms

Sign up to save your podcasts

Episode 695: Monoclonal antibodies for Alzheimer disease: A lack of clinically meaningful benefits, plus significant harms

Episode 695: Monoclonal antibodies for Alzheimer disease: A lack of clinically meaningful benefits, plus significant harms

More shows like POEM of the Week Podcast

JAMA Clinical Reviews

AFP: American Family Physician Podcast

The Curbsiders Internal Medicine Podcast

Up First from NPR